FI935297A0 - Kinuklidinderivat - Google Patents

Kinuklidinderivat

Info

Publication number
FI935297A0
FI935297A0 FI935297A FI935297A FI935297A0 FI 935297 A0 FI935297 A0 FI 935297A0 FI 935297 A FI935297 A FI 935297A FI 935297 A FI935297 A FI 935297A FI 935297 A0 FI935297 A0 FI 935297A0
Authority
FI
Finland
Prior art keywords
kinuklidinderivat
Prior art date
Application number
FI935297A
Other languages
English (en)
Other versions
FI935297A (fi
FI114475B (fi
Inventor
Fimitaka Ito
Hiroshi Kondo
Kaoru Shimada
Masami Nakane
John A Lowe Iii
Terry J Rosen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24845673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI935297(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of FI935297A publication Critical patent/FI935297A/fi
Publication of FI935297A0 publication Critical patent/FI935297A0/fi
Application granted granted Critical
Publication of FI114475B publication Critical patent/FI114475B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI935297A 1991-05-31 1993-11-29 Menetelmä uusien terapeuttisesti käyttökelpoisten kinuklidiinijohdannaisten valmistamiseksi FI114475B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70840491A 1991-05-31 1991-05-31
US70840491 1991-05-31
US9203317 1992-04-28
PCT/US1992/003317 WO1992021677A1 (en) 1991-05-31 1992-04-28 bibNUCLIDINE DERIVATIVES

Publications (3)

Publication Number Publication Date
FI935297A FI935297A (fi) 1993-11-29
FI935297A0 true FI935297A0 (fi) 1993-11-29
FI114475B FI114475B (fi) 2004-10-29

Family

ID=24845673

Family Applications (1)

Application Number Title Priority Date Filing Date
FI935297A FI114475B (fi) 1991-05-31 1993-11-29 Menetelmä uusien terapeuttisesti käyttökelpoisten kinuklidiinijohdannaisten valmistamiseksi

Country Status (41)

Country Link
US (3) US5807867A (fi)
EP (1) EP0587723B1 (fi)
JP (2) JPH0733386B2 (fi)
KR (1) KR100214905B1 (fi)
CN (1) CN1048492C (fi)
AP (1) AP299A (fi)
AT (1) ATE135006T1 (fi)
AU (1) AU657552B2 (fi)
BG (1) BG61694B1 (fi)
BR (1) BR9206073A (fi)
CA (1) CA2102179C (fi)
CZ (1) CZ281403B6 (fi)
DE (4) DE122006000066I1 (fi)
DK (1) DK0587723T3 (fi)
EG (1) EG19944A (fi)
ES (1) ES2084361T3 (fi)
FI (1) FI114475B (fi)
GR (1) GR3019687T3 (fi)
GT (1) GT199200028A (fi)
HU (1) HU217548B (fi)
IE (1) IE72473B1 (fi)
IL (1) IL102008A (fi)
IS (1) IS1611B (fi)
LU (1) LU91293I2 (fi)
MA (1) MA22539A1 (fi)
MX (1) MX9202554A (fi)
NL (1) NL300250I2 (fi)
NO (2) NO302701B1 (fi)
NZ (2) NZ242956A (fi)
OA (1) OA09867A (fi)
PL (1) PL171379B1 (fi)
PT (1) PT100546B (fi)
RO (1) RO110499B1 (fi)
RU (1) RU2103269C1 (fi)
SK (1) SK390692A3 (fi)
TW (1) TW204349B (fi)
UA (1) UA27776C2 (fi)
UY (1) UY23422A1 (fi)
WO (1) WO1992021677A1 (fi)
YU (1) YU48995B (fi)
ZA (1) ZA923942B (fi)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0587723T3 (da) * 1991-05-31 1996-04-01 Pfizer Quinuclidinderivater
UA39168C2 (uk) * 1991-06-20 2001-06-15 Пфайзер, Інк. Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі
AU4224993A (en) * 1992-08-19 1994-03-15 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
DE69307340T2 (de) * 1992-11-12 1997-04-24 Pfizer Chinuclidin derivat als substanz p antagonist
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0659409A3 (en) * 1993-11-23 1995-08-09 Pfizer Substance P antagonists for the inhibition of angiogenesis.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
NZ329807A (en) * 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
CA2321155A1 (en) * 1998-03-19 1999-09-23 Takayuki Doi Heterocyclic compounds, their production and use as tachykinin receptor antagonists
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
ES2304984T3 (es) 1999-11-03 2008-11-01 Amr Technology, Inc. Tetra-hidroisoquinolinas de sustitucion arilica y heteroarilica y su utilizacion para bloquear la recaptacion de norepinefrina, dopamina y serotonina.
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
EP1299393A2 (en) 2000-07-11 2003-04-09 Bristol-Myers Squibb Pharma Company 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
HUP0401154A2 (hu) * 2001-07-20 2004-10-28 Pfizer Products Inc. NK-1 receptor antagonisták használata kutyák, macskák és lovak nemkívánatos viselkedésének módosítására
US6686507B2 (en) 2002-03-06 2004-02-03 Pfizer Inc Purification of 2-methoxy-5-trifluoromethoxybenzaldehyde
US6861526B2 (en) * 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
US20050136487A1 (en) * 2003-10-27 2005-06-23 Meyer Donald W. Transmissible spongiform encephalopathy detection in cervids, sheep and goats
WO2005051919A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
JP5021318B2 (ja) * 2004-01-30 2012-09-05 ファイザー・プロダクツ・インク β−シクロデキストリンを液体投薬形態に用いて多用量製剤を達成するための抗菌性防腐剤
AU2005216706B2 (en) 2004-01-30 2007-11-29 Pfizer Products Inc. NK-1 receptor antagonists anesthesia recovery
SI1713801T1 (sl) * 2004-02-02 2008-04-30 Pfizer Prod Inc Postopek priprave 1-(2S,3S)-2-benzhidril-N-(5-terc-butil-2-metoksibenzil)kinuklidin-3- amina
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
KR101589551B1 (ko) 2005-07-15 2016-02-02 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
PL2109608T3 (pl) 2007-01-10 2011-08-31 Msd Italia Srl Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
KR20100126467A (ko) 2008-03-03 2010-12-01 타이거 파마테크 티로신 키나아제 억제제
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
SI2606134T1 (sl) 2010-08-17 2019-08-30 Sirna Therapeutics, Inc. RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
IN2013MN02170A (fi) 2011-04-21 2015-06-12 Piramal Entpr Ltd
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
BR112019021125A2 (pt) 2017-04-10 2020-05-12 Chase Therapeutics Corporation Combinação de antagonista de nk1 e método para tratamento de sinucleinopatias
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法
MA49524A (fr) 2017-06-30 2021-05-26 Chase Therapeutics Corp Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
AU2019223237A1 (en) 2018-02-26 2020-09-03 Ospedale San Raffaele S.R.L. NK-1 antagonists for use in the treatment of ocular pain
KR102102109B1 (ko) * 2018-07-10 2020-04-20 성균관대학교산학협력단 N-벤즈히드릴 퀴뉴클리딘 유도체를 포함하는 나트륨 누출 채널 억제용 조성물
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2021180885A1 (en) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
HUT62891A (en) * 1990-06-01 1993-06-28 Pfizer Process for producing 3-amino-2-arylquinuclidine compounds and pharmaceuticql composition comprising such compounds
DE4026743A1 (de) * 1990-08-24 1992-02-27 Teves Gmbh Alfred Blockiergeschuetzte bremsanlage fuer kraftfahrzeuge
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
DK0587723T3 (da) * 1991-05-31 1996-04-01 Pfizer Quinuclidinderivater
EP0916346A3 (en) * 1991-09-20 2000-12-06 Glaxo Group Limited NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
US5990125A (en) * 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer
EP0785198B1 (de) * 1996-01-19 2000-07-05 Lonza Ag Verfahren zur Herstellung von optisch aktivem 3-Chinuclidinol

Also Published As

Publication number Publication date
IS1611B (is) 1996-10-18
EG19944A (en) 1997-02-27
IE72473B1 (en) 1997-04-23
IL102008A (en) 1995-12-08
CZ281403B6 (cs) 1996-09-11
AP9200384A0 (en) 1992-07-31
IS3871A (is) 1992-12-02
CA2102179C (en) 1998-10-27
US5807867A (en) 1998-09-15
HU9303393D0 (en) 1994-03-28
KR100214905B1 (ko) 1999-08-02
US5939433A (en) 1999-08-17
NO302701B1 (no) 1998-04-14
NO2007003I1 (no) 2007-03-26
GR3019687T3 (en) 1996-07-31
US6222038B1 (en) 2001-04-24
JP2645225B2 (ja) 1997-08-25
CA2102179A1 (en) 1992-12-01
SK278788B6 (sk) 1998-02-04
CZ390692A3 (en) 1994-02-16
CN1048492C (zh) 2000-01-19
FI935297A (fi) 1993-11-29
ES2084361T3 (es) 1996-05-01
MX9202554A (es) 1992-11-01
UY23422A1 (es) 1992-11-12
ZA923942B (en) 1993-11-29
PT100546A (pt) 1993-08-31
NO934312L (no) 1993-11-29
NO2007003I2 (no) 2011-04-18
JPH06504292A (ja) 1994-05-19
YU56492A (sh) 1995-03-27
FI114475B (fi) 2004-10-29
AP299A (en) 1994-01-14
NZ242956A (en) 1995-06-27
YU48995B (sh) 2003-04-30
AU1990192A (en) 1993-01-08
HUT70151A (en) 1995-09-28
RU2103269C1 (ru) 1998-01-27
UA27776C2 (uk) 2000-10-16
HU217548B (hu) 2000-02-28
DE122006000066I2 (de) 2007-12-06
DK0587723T3 (da) 1996-04-01
AU657552B2 (en) 1995-03-16
NZ270673A (en) 1997-07-27
JPH07285965A (ja) 1995-10-31
IE921729A1 (en) 1992-12-02
DE122006000066I1 (de) 2007-03-22
BG61694B1 (bg) 1998-03-31
EP0587723A1 (en) 1994-03-23
WO1992021677A1 (en) 1992-12-10
CN1067428A (zh) 1992-12-30
PT100546B (pt) 1999-12-31
DE9290063U1 (de) 1994-02-24
SK390692A3 (en) 1998-02-04
IL102008A0 (en) 1992-12-30
EP0587723B1 (en) 1996-03-06
DE69208877D1 (de) 1996-04-11
BR9206073A (pt) 1994-12-06
TW204349B (fi) 1993-04-21
PL171379B1 (en) 1997-04-30
ATE135006T1 (de) 1996-03-15
RO110499B1 (ro) 1996-01-30
NO934312D0 (no) 1993-11-29
LU91293I2 (fr) 2007-02-06
OA09867A (en) 1994-08-15
DE69208877T2 (de) 1996-07-25
BG98248A (bg) 1994-07-29
JPH0733386B2 (ja) 1995-04-12
GT199200028A (es) 1993-11-20
MA22539A1 (fr) 1992-12-31
NL300250I2 (nl) 2007-03-01
NL300250I1 (nl) 2007-02-01

Similar Documents

Publication Publication Date Title
DE69212332D1 (de) Farbball
DE59206583D1 (de) Windsichter
FI935297A (fi) Kinuklidinderivat
ATE137279T1 (de) Stoffauflauf
DE59209950D1 (de) Flaschendispenser
DE69218585D1 (de) Anzeigetafel
BR9204511A (pt) Recolhedor-enrolador
DE59208716D1 (de) Lymphoides cd30-antigen
DE59207013D1 (de) Sportschuh
DE69126968D1 (de) Tamburin
ATA39792A (de) Maehwerk
ATE163916T1 (de) Ethyl-6-formyloxy-4-hexenoat
ATA9892A (de) Formstein
ATA67791A (de) Rollski
BR9201945A (pt) Filatorio
NO923076D0 (no) Espagnolettanordning
CA68725S (fr) Mobilier-jeu
BR9100694A (pt) Pareoteca
BR9104416A (pt) Supercalibragem
BR7102423U (pt) Mic-lav
BR9100002A (pt) Candress
BR9100265A (pt) Assadeira multiutilitaria
BR9100610A (pt) Sandalia ortopedica magnetica
BR7102174U (pt) Refresqueira
BR9100759A (pt) Maca-cadeira

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 114475

Country of ref document: FI

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20070011

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 296

Extension date: 20170428

MA Patent expired